Autologous Cell Therapy Manufacturing Facilities of the Future

Introduction The race to develop the first CAR-T therapy, resulting in the approvals of Novartis’ Kymriah and Kite/Gilead’s Yescarta in August and October of 2017, demonstrated the potential of cell therapy to address unmet medical needs, and generated considerable excitement about cell therapy ...

To read the full article and other articles in this issue, please register for a free account or log in.

We will not sell or give your information to a third party. See our Privacy Policy



Subscribe to our FREE newsletter

We will not sell or give your information to a third party. See our Privacy Policy